am 251 has been researched along with Sensation Disorders in 1 studies
AM 251: an analog of SR141716A; structure given in first source
AM-251 : A carbohydrazide obtained by formal condensation of the carboxy group of 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-1H-pyrazole-3-carboxylic acid with the amino group of 1-aminopiperidine. An antagonist at the CB1 cannabinoid receptor.
Sensation Disorders: Disorders of the special senses (i.e., VISION; HEARING; TASTE; and SMELL) or somatosensory system (i.e., afferent components of the PERIPHERAL NERVOUS SYSTEM).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ballmaier, M | 1 |
| Bortolato, M | 1 |
| Rizzetti, C | 1 |
| Zoli, M | 1 |
| Gessa, G | 1 |
| Heinz, A | 1 |
| Spano, P | 1 |
1 other study available for am 251 and Sensation Disorders
| Article | Year |
|---|---|
Cannabinoid receptor antagonists counteract sensorimotor gating deficits in the phencyclidine model of psychosis.
Topics: Animals; Brain; Cannabinoid Receptor Antagonists; Disease Models, Animal; Dose-Response Relationship | 2007 |